AI/ML Innovations Inc. Announces Revocation of MCTO

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

VICTORIA, BC / ACCESSWIRE / October 2, 2024 / AI/ML Innovations Inc. (“AI/ML” or the “Company“) (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) is pleased to announce that the Company’s principal regulator, the British Columbia Securities Commission (“BCSC“) has lifted the Management Cease Trade Order (“MCTO“) it had previously granted the Company on August 29, 2024 under National Policy 12-203 Management Cease Trade Orders (“NP 12-203“), as the Company has now successfully completed all requisite filings for its annual and interim financial periods ending April 30, 2024 and July 31, 2024, respectively. Revoking the MCTO means members of management are no longer prevented from trading the Company’s common shares.

The MCTO had been granted in conjunction with the Company’s anticipated late filings of its annual audited financial statements, management’s discussion and analysis and related certifications for the financial year ended April 30, 2024, which were originally due August 28, 2024 (collectively, the “Annual Filings“).

As a result of circumstances reasonably linked to the Company’s delay in filing the Annual Filings, the Company anticipated being unable to meet the deadline for filing its interim unaudited financial statements, interim management’s discussion and analysis and related certifications for the three-month period ended July 31, 2024 (collectively, the “Interim Filings“, and together with the Annual Filings, the “Required Filings“). Fortunately, the Company was able to complete the Interim Filings in accordance with Canadian securities law and regulation. Under the securities laws of the provinces in which AI/ML is a reporting issuer, the Interim Filings were to be filed by October 1, 2024.

The Company remains committed to timely financial transparency and wishes to thank its shareholders, auditors and the BCSC, for their continued trust.

AI/ML’s Required Filings are publicly available on www.sedarplus.ca.

###

About AI/ML Innovations Inc. https://aiml-innovations.com/

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge Inc. (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML), NeuralCloud Solutions Inc. (100% owned by AIML), and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company’s stakeholders. AI/ML’s shares are traded on the Canadian Securities Exchange under the symbol “AIML”, the OTCQB Venture Market under “AIMLF”, and the Frankfurt Stock Exchange under “42FB”.

On behalf of the Board of Directors

Tim Daniels, Executive Chairman

For more information about AI/ML Innovations:

For detailed information please see AI/ML’s website or the Company’s filed documents at www.sedarplus.ca

For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: AI/ML Innovations, Inc.

Staff

Recent Posts

NJ Rallies Investment Power, Leveraging Capital from Garden State Venture Partners to Drive MedTech and Maternal Health Innovation

GLASSBORO, N.J.--(BUSINESS WIRE)--Two transformative healthcare announcements this week mark a new era for New Jersey’s…

3 hours ago

Revival Healthcare Capital Announces Strategic Partnership to Accelerate External Innovation in Robotics With up to $458 Million Joint Investment With Olympus Into Co-Founded New Company Swan EndoSurgical

AUSTIN, Texas--(BUSINESS WIRE)--Revival Healthcare Capital (Revival), an investment firm focused on transformative external innovation partnerships…

3 hours ago

Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to…

6 hours ago

HCA Healthcare Reports Second Quarter 2025 Results

Raises 2025 GuidanceNASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and operating results…

6 hours ago

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2024 Results

Q4 Fiscal 2024 Highlights1Revenue of $1.2 million, a 16.4% increase over Q3 2024Gross profit of…

6 hours ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO),…

9 hours ago